Aptorum Group Limited
$0.9
▼
-2.93%
2026-04-21 05:20:01
www.aptorumgroup.com
NCM: APM
Explore Aptorum Group Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.21 M
Current Price
$0.9
52W High / Low
$4.47 / $0.65
Stock P/E
—
Book Value
$2.84
Dividend Yield
—
ROCE
-12.89%
ROE
-10.79%
Face Value
—
EPS
$-0.19
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1
Beta
-0.01
Debt / Equity
25.05
Current Ratio
0.78
Quick Ratio
0.78
Forward P/E
-1.28
Price / Sales
—
Enterprise Value
$-1.97 M
EV / EBITDA
1.26
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 2. | Tvardi Therapeutics, Inc. | $3.22 | — | $30.72 M | — | -127.18% | -2.38% | $43.65 / $2.75 | $2.23 |
| 3. | Oncolytics Biotech Inc. | $1.11 | — | $163.05 M | — | -1939.57% | 11480.64% | $1.85 / $0.45 | $0 |
| 4. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 5. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 6. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 7. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -0.83 M | -0.59 M | 0.56 M | -0.69 M |
| Net Profit | -0.31 M | -0.61 M | -0.92 M | -0.7 M |
| EPS in Rs | -0.05 | -0.1 | -0.14 | -0.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.43 M | 1.3 M |
| Operating Profit | -1.82 M | -3 M | -10.6 M | -17.17 M |
| Net Profit | -1.36 M | -4.27 M | -2.82 M | -9.8 M |
| EPS in Rs | -0.21 | -0.67 | -0.45 | -1.54 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 18.69 M | 16.13 M | 20.64 M | 20.87 M |
| Total Liabilities | 4.9 M | 4.35 M | 5.26 M | 13.03 M |
| Equity | 23.16 M | 21.13 M | 24.85 M | 15.71 M |
| Current Assets | 3.59 M | 0.96 M | 2.48 M | 7.07 M |
| Current Liabilities | 4.59 M | 4.34 M | 2.1 M | 12.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -1.84 M | -1.19 M | -7.72 M | -12.32 M |
| Investing CF | 0 M | 0.06 M | 0.62 M | 2.44 M |
| Financing CF | 4.42 M | 0 M | 4.09 M | 6.63 M |
| Free CF | -1.84 M | -1.19 M | -7.73 M | -12.51 M |
| Capex | — | — | -0 M | -0.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -66.71% | — | — |
| Earnings Growth % | -51.09% | 71.18% | — | — |
| Profit Margin % | — | -654.8% | -756.2% | — |
| Operating Margin % | — | -2457.53% | -1325.24% | — |
| Gross Margin % | — | 2.45% | 6.18% | — |
| EBITDA Margin % | — | -2138.18% | -1205.12% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-01-23 | 1:0.1 |